home hero

For your mCRPC patients after docetaxel

SEIZE THE WINDOW OF OPPORTUNITY

When you see disease progression, reach for JEVTANA1,2

SEE EFFICACY & SAFETY

NCCN

DESIGNATED CATEGORY 1

NCCN

Cabazitaxel (JEVTANA) is a National Comprehensive Cancer Network® (NCCN®) designated Category 1 preferred regimen following docetaxel and novel hormonal therapy for patients with metastatic castration-resistant prostate cancer (mCRPC).3



CARD Results

This trial (N=255) compared JEVTANA vs
a second androgen-signaling-targeted
inhibitor (ASTI) after a docetaxel-
containing regimen.2

SEE EFFICACY & SAFETY

TROPIC Results

The pivotal trial (N=755) validated
JEVTANA as a treatment in mCRPC after
docetaxel.1,4

SEE EFFICACY & SAFETY

PROSELICA Results

This trial (N=1200) established
JEVTANA 20 mg/m2 as the recommended starting dose.1

SEE EFFICACY & SAFETY

Ready to start a patient on JEVTANA in your practice?


See a detailed overview of treatment with JEVTANA

Hear Dr Slovin share an example of an mCRPC patient who she is currently treating with JEVTANA.

Susan Slovin, MD, PhD
Medical Oncologist
Memorial Sloan Kettering Cancer Center


WATCH VIDEO


Learn about mechanisms of progression

ABOUT mCRPC